Target Information

LBO France has announced the acquisition of a majority stake in Hemodia, a leading French company specializing in single-use medical and electro-medical devices. Founded in 1985, Hemodia focuses on designing and manufacturing sets for treatment, primarily in dialysis and infusion, along with pumps and tubing intended for arthroscopy in minimally invasive surgical procedures. The company, employing around 500 people, operates five production sites located in France (Toulouse) and Tunisia, which are equipped with advanced sterilization capabilities and optimized logistics to meet the stringent demands of the healthcare market.

Hemodia has achieved an average annual growth rate of 8%, establishing a solid market position in high-potential segments, especially in the French dialysis market, thanks to its tailored offerings. Additionally, its robust research and development capabilities have positioned Hemodia as a key player in the arthroscopic pump sector with internally developed solutions. The company reports a revenue of approximately 50 million euros.

Industry Overview

The medical devices industry in France is characterized by continuous growth, driven by advances in technology and a rising demand for innovative healthcare solutions. France is known for its strong regulatory environment which ensures high standards, thus providing a fertile ground for companies like Hemodia to thrive. With an aging population and increasing health awareness, the demand for quality medical devices is projected to rise steadily, fueling market expansion.

Government initiatives and funding opportunities further bolster the medical devices sector, as they often prioritize healthcare innovations that improve patient outcomes. This support encourages research and the development of new medical technologies, ensuring that companies are equipped to meet evolving market needs.

Currently, the French medical device market is witnessing significant trends toward digitization and sustainability, as healthcare stakeholders increasingly emphasize not only the efficacy of medical devices but also their environmental impact. Companies are actively exploring cleaner production methods and looking to minimize their ecological footprints, reflecting a broader global trend in the industry.

Rationale Behind the Deal

LBO France aims to leverage this acquisition to accelerate Hemodia’s growth in Europe, particularly through external growth operations, focusing on Italy as a priority market. This collaboration is expected to harness LBO France’s expertise in acquisitions and its multi-geographic platform, further enhancing Hemodia's Italian market presence. In addition to European expansion, innovation and product diversification remain core strategic priorities for the company.

Moreover, Hemodia’s proactive approach toward sustainable development and environmental compliance aligns well with LBO France’s commitment to strengthening its ESG initiatives, facilitating the introduction of new projects focused on sustainability.

Investor Information

LBO France is a renowned pioneer in private equity in France, operating as a multi-specialist investment platform that spans several sectors and countries. With interests in Private Equity, Real Estate, Venture Capital, and public markets, LBO France has expanded its reach across Europe, particularly in Italy through Polis SGR, as well as into Africa via CGF bourse. Completely owned by its managers, the firm upholds its leadership in the private equity space while actively engaging in initiatives promoting climate and gender parity within the investment community.

View of Dealert

The acquisition of Hemodia by LBO France presents a compelling investment opportunity, primarily due to Hemodia's robust market positioning and consistent growth trajectory. With a revenue of 50 million euros and solid annual growth, the company's focus on R&D and innovative solutions in its field enhances its potential for success.

Furthermore, LBO France's commitment to supporting Hemodia's expansion, particularly in international markets like Italy, indicates a strategic move to tap into broader growth opportunities. The added expertise from LBO will likely enhance operational capabilities and market reach, ensuring robust competitive positioning.

Investments in sustainability and ESG-driven initiatives in alignment with market trends not only position Hemodia as a forward-thinking player in the industry but also serve to attract market interest and potential collaborations moving forward. In conclusion, with dedicated management leading the charge and significant backing from LBO France, the deal reflects a strong collaborative framework aimed at accelerating growth and innovation.

View Original Article